Katherine M.W. Pisters, M.D., F.A.C.P.

Peer-Reviewed Articles

1. Pisters K, Kris MG, Gaspar LE, Ismaila N, Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA NSCLC Guideline Expert Panel. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 40(10):1127-1129, 2022. e-Pub 2022. PMID: 35167335.
2. Fung AS, Graham DM, Chen EX, Stockley TL, Zhang T, Le LW, Albaba H, Pisters KM, Bradbury PA, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendi S, Gill S, Sawczak M, Law JH, Leighl NB. A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung Cancer 157:21-29, 2021. e-Pub 2021. PMID: 34052705.
3. Pezzi TA, Schwartz DL, Pisters KMW, Mohamed ASR, Welsh JW, Chang JY, Liao Z, Gandhi SJ, Byers LA, Minsky BD, Fuller CD, Chun SG. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open 3(4):e203277, 2020. e-Pub 2020. PMID: 32320035.
4. O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA. Uncommon EGFR mutations in advanced non-small cell lung cancer. Lung Cancer 109:137-144, 2017. e-Pub 2017. PMID: 28577943.
5. Halasz LM, Uno H, Hughes M, D'Amico T, Dexter EU, Edge SB, Hayman JA, Niland JC, Otterson GA, Pisters KM, Theriault R, Weeks JC, Punglia RS. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer 122(13):2091-100, 2016. e-Pub 2016. PMID: 27088755.
6. Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera E. Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage 52(1):8-16.e1, 2016. e-Pub 2016. PMID: 27330023.
7. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw 14(7):825-36, 2016. PMID: 27407123.
8. Valle LF, Jagsi R, Bobiak SN, Zornosa C, D'Amico TA, Pisters KM, Dexter EU, Niland JC, Hayman JA, Kapadia NS. Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. Int J Radiat Oncol Biol Phys 94(2):360-7, 2016. e-Pub 2015. PMID: 26853344.
9. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw 12(12):1738-61, 2014. PMID: 25505215.
10. Kernstine KH, Moon J, Kraut MJ, Pisters KM, Sonett JR, Rusch VW, Thomas CR, Waddell TK, Jett JR, Lyss AP, Keller SM, Gandara DR, American College of Surgeons Oncology Group, Cancer and Leukemia Group B, Eastern Cooperative Oncology Group, North Central Cancer Treatment Group, National Cancer Institute of Canada Clinical Trials Group, and Southwest Oncology Group. Trimodality Therapy for Superior Sulcus Non-Small Cell Lung Cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg. e-Pub 2014. PMID: 24980603.
11. Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer 15(3):197-201, 2014. e-Pub 2013. PMID: 24492162.
12. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383(9928):1561-71, 2014. e-Pub 2014. PMID: 24576776.
13. Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, University of Texas MD Anderson Lung Cancer Collaborative Group. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. PMID: 24384493.
14. Escalante CP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J 20(1):8-14, 2014. PMID: 24445757.
15. Milbury K, Badr H, Fossella F, Pisters KM, Carmack CL. Longitudinal associations between caregiver burden and patient and spouse distress in couples coping with lung cancer. Support Care Cancer 21(9):2371-9, 2013. e-Pub 2013. PMID: 23546537.
16. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol 31(27):3320-6, 2013. e-Pub 2013. PMID: 23980091.
17. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw 11(6):645-53; quiz 653, 2013. PMID: 23744864.
18. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 11(5):562-76, 2013. PMID: 23667206.
19. Ferketich AK, Niland JC, Mamet R, Zornosa C, D'Amico TA, Ettinger DS, Kalemkerian GP, Pisters KM, Reid ME, Otterson GA. Smoking status and survival in the national comprehensive cancer network non-small cell lung cancer cohort. Cancer 119(4):847-53, 2013. e-Pub 2012. PMID: 23023590.
20. Zornosa C, Vandergrift JL, Kalemkerian GP, Ettinger DS, Rabin MS, Reid M, Otterson GA, Koczywas M, D'Amico TA, Niland JC, Mamet R, Pisters KM. First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. J Natl Compr Canc Netw 10(7):847-56, 2012. PMID: 22773800.
21. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG, University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7(5):825-32, 2012. PMID: 22481232.
22. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant pleural mesothelioma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 10(1):26-41, 2012. PMID: 22223867.
23. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network. Thymic malignancies. J Natl Compr Canc Netw 8(11):1302-15, 2010. PMID: 21081786.
24. Pisters KM, Vallières E, Crowley JJ, Franklin WA, Bunn PA, Ginsberg RJ, Putnam JB, Chansky K, Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol 28(11):1843-9, 2010. e-Pub 2010. PMID: 20231678.
25. Kassis ES, Vaporciyan AA, Swisher SG, Correa AM, Bekele BN, Erasmus JJ, Hofstetter WL, Komaki R, Mehran RJ, Moran CA, Pisters KM, Rice DC, Walsh GL, Roth JA. Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population. J Thorac Cardiovasc Surg 138(2):412-418.e1-2, 2009. e-Pub 2009. PMID: 19619787.
26. Bolton WD, Rice DC, Correa AM, Hofstetter W, Komaki R, Mehran R, Pisters K, Roth JA, Vaporciyan AA, Walsh GL, Swisher SG. Influence of age on choice of therapy and surgical outcomes in patients with nonsmall cell lung cancer. Am Surg 75(7):598-603; discussion 603-4, 2009. PMID: 19655604.
27. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ. Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. J Clin Oncol 27(18):3007-13, 2009. e-Pub 2009. PMID: 19364962.
28. Bolton WD, Rice DC, Goodyear A, Correa AM, Erasmus J, Hofstetter W, Komaki R, Mehran R, Pisters K, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Weaver J, Rhines L. Superior sulcus tumors with vertebral body involvement: a multimodality approach. J Thorac Cardiovasc Surg 137(6):1379-87, 2009. PMID: 19464452.
29. Carmack Taylor CL, Badr H, Lee JH, Fossella F, Pisters K, Gritz ER, Schover L. Lung cancer patients and their spouses: psychological and relationship functioning within 1 month of treatment initiation. Ann Behav Med 36(2):129-40. e-Pub 2008. PMID: 18797978.
30. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 73(1):119-27. e-Pub 2008. PMID: 18556142.
31. Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, Wistuba II, Koo JS.. Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Non-Small Cell Lung Cancer. Cancer Res 68(15):6065-73, 2008. PMID: 18676828.
32. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132(3 Suppl):234S-242S, 2007. PMID: 17873171.
33. Pisters KM, Darling G. The IASLC Lung Cancer Staging Project: "the nodal zone". J Thorac Oncol 2(7):583-4, 2007. PMID: 17607110.
34. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS, Bruera E. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107(12):2949-57, 2006. PMID: 17103445.
35. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5)(5):326-31, 2006. PMID: 16640804.
36. Strasser F, Palmer JL, Scholver LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Wiley JS, Bruera E. The impact of hypogonadism and automic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot stud. Cancer 107(12):2949-2957, 2006.
37. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 2005. PMID: 16028213.
38. Erasmus JJ, Truong MT, Smythe WR, Munden RF, Marom EM, Rice DC, Vaporciyan AA, Walsh GL, Sabloff BS, Broemeling LD, Stevens CW, Pisters KM, Podoloff DA, Macapinlac HA. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J Thorac Cardiovasc Surg 129(6):1364-70, 2005. PMID: 15942579.
39. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 23(14):3270-8, 2005. PMID: 15886314.
40. Zinner RG, Fossella FV, Gladish VW, Glisson BS, Blumenschein Jr. GR, Papadimitrakopoulou VA, Pisters KMW, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 104(11):2449-2456, 2005. PMID: 16258975.
41. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summery C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant non-small cell lung cancer. Cancer 104(3):561-69, 2005.
42. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 2004. PMID: 15050312.
43. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44(1):99-110, 2004. PMID: 15013588.
44. Bruera E, Sweeney C, Willey J, Palmer JL, Strasser F, Morice RC, Pisters K. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 17(8):659-63, 2003. PMID: 14694916.
45. Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer. Clin Adv Hematol Oncol 1(9):533-7, 2003. PMID: 16258445.
46. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 2003. PMID: 14596703.
47. Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Clin Cancer Res 9(6):2085-91, 2003. PMID: 12796372.
48. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003. PMID: 12538456.
49. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 2002. PMID: 12124835.
50. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 2002. PMID: 11917284.
51. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (Iressa) in non-small-cell lung cancer. Clin Lung Cancer 3(1):27-32, 2001. PMID: 14656386.
52. Siegenthaler MP, Pisters KM, Merriman KW, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Smythe WR, Putnam JB, Jr. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 71(4):1105-11; discussion 1111-2, 2001. PMID: 11308144.
53. Laurie SA, Pfister DG, Kris MG, Tong WP, Chronowski G, Pisters KM, Heelan RT, Sirotnak FM. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin. Clin Cancer Res 7(3):501-9, 2001. PMID: 11297240.
54. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19(6):1830-8, 2001. PMID: 11251015.
55. Yen N, Ioannides CG, Xu K, Swisher SG, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano RJ, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Nguyen D, Perez-Soler R, Pisters KM, Putnam JB, Jr, Schrump DS, Shin DM, Walsh GL, Roth JA. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). Cancer Gene Ther 7(4):530-6, 2000. PMID: 10811470.
56. Pisters KM, Ginsberg RJ, Giroux DJ, Putnam JB, Jr, Kris MG, Johnson DH, Roberts JR, Mault J, Crowley JJ, Bunn PA, Jr. Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 119(3):429-39, 2000. PMID: 10694600.
57. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J, Roth J. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18(3):609-22, 2000. PMID: 10653876.
58. Ng KK, Kris MG, Ginsberg RJ, Heelan RT, Pisters KM, Miller VA, Grant SC, Bains M, Rusch V, Rosenzweig KE, Martini N. Induction chemotherapy employing dose-intense cisplatin with mitomycin and vinblastine (MVP400), followed by thoracic surgery or irradiation, for patients with stage III nonsmall cell lung carcinoma. Cancer 86(7):1189-97, 1999. PMID: 10506703.
59. Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KM, Shin DM, Hong WK. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma. J Clin Oncol 17(8):2309-15, 1999. PMID: 10561292.
60. Rigas JR, Kris MG, Miller VA, Pisters KM, Heelan RT, Grant SC, Fennelly DW, Chou TC, Sirotnak FM. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Ann Oncol 10(5):601-3, 1999. PMID: 10416013.
61. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91(9):763-71, 1999. PMID: 10328106.
62. Pizzo BA, Pisters KM, Miller VA, Grant SC, Baltzer L, Hinckley L, Kris MG. Oral cisapride for the control of delayed vomiting following high-dose cisplatin. Support Care Cancer 7(1):44-6, 1999. PMID: 9926974.
63. Shin DM, Walsh GL, Komaki R, Putnam JB, Nesbitt J, Ro JY, Shin HJ, Ki KH, Wimberly A, Pisters KM, Schrump D, Gregurich MA, Cox JD, Roth JA, Hong WK. A multidisciplinary approach to therapy for unresectable malignant thymoma. Ann Intern Med 129(2):100-4, 1998. PMID: 9669967.
64. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA. Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16(1):81-5, 1998. PMID: 9740548.
65. Shade RJ, Pisters KMW, Huber MH, Fossella F, Perez-Soler R, Shin DM, Kurie J, Glisson B, Lippman S, Lee JS. Phase I study of paclitaxel administered by ten-day continuous infusion. Invest New Drugs 16(3):237-43, 1998. PMID: 10360603.
66. Kris, MG, Pisters KMW, Pizzo BA. Delayed emesis following cisplatin: Progress and prospects. . Pharm Therap:12S-17S, 1997.
67. Miller VA, Rigas JR, Tong WP, Reid JR, Pisters KM, Grant SC, Heelan RT, Kris MG. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer. Cancer Chemother Pharmacol 40(5):415-8, 1997. PMID: 9272118.
68. Roth, JA, Swisher SG, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene replacement for lung cancer. . Lung Cancer 18(2):76, 1997.
69. Roth, JA, Swisher SG, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar AK, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters K, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy strategies for lung cancer. Lung Cancer 198(2):141, 1997.
70. Pisters KM, Kris MG, Tyson LB, Clark RA, Gralla RJ. Dose-ranging trial of zacopride: the emetic antiemetic?. J Natl Cancer Inst 84:717-8, 1992. PMID: 1569606.
71. Sejpal S, Komaki R, Chang JY, McAleer MF, Bucci MK, Liao Z, Wei X, Allen PK, Tsa A, Kim ES, Pisters K, Gillin M, Cox JD. Proton beam therapy and concurrent chemotherapy for non-small cell lung cancer.

Invited Articles

1. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw 14(3):255-64, 2016. PMID: 26957612.
2. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw 13(5):515-24, 2015. PMID: 25964637.
3. Pisters KMW. Adjuvant chemotherapy for resected non-small cell lung cancer. Oncology, 2005.
4. Johnson, FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-Dense Therapy With a Novel Irinotecan Regimen for Small-Cell Lung Cancer. Oncology (Williston Park) 17(7):17-21, 2003. PMID: 12886869.
5. Pisters KMW. Stage I/II non-small cell lung cancer: Is there a role for combined-modality therapy?. ASCO 2002 Educational Book:465-470, 2002.
6. Pisters KMW . Adjuvant and neoadjuvant therapy for early-stage non-small cell lung cancer. Sem Oncol 28(4):23-28, 2001.
7. Pisters KMW. Neoadjuvant therapy for early stage lung cancer. The Society of Thoracic Surgeons, 2001.
8. Pisters KMW. Adjuvant and neoadjuvant therapy for early stage non-small cell lung cancer. Semin Oncol 28(14):23-28, 2001.
9. Pisters KMW . Adjuvant therapy after definitive surgery. Lung Cancer 34(1), 2001.
10. Pisters KMW. Editorial on adjuvant chemotherapy. Hematology & Oncology, 2001.
11. Pisters KMW. The role of chemotherapy in early stage (stage I and II) resectable non-small cell lung cancer. Semin Radiat Oncol 10(4):274-279, 2000.
12. Pisters KMW. Induction chemotherapy for early-stage lung cancer. Lung Cancer 29(2):126, 2000.
13. Pisters KMW. Adjuvant systemic and local therapy in the postoperative setting: Is there benefit?. ASCO 2000 Clinical Practice Forum Book:3-7, 2000.
14. Pisters KMW. Early stage NSCLC: Updates on Management and therapy. Medscape Oncology Conference Summaries, 1999.
15. Pisters KMW. Combined modality therapy for Lung Cancer. Medscape Oncology Conference Summaries, 1999.
16. Pisters KMW. Phase III Intergroup trial: Induction paclitaxel/carboplatin chemotherapy followed by surgery vs. surgery only in early-stage non-small cell lung cancer. Thoracic Oncology Newsletter, 1999.
17. Swisher, SG, Roth JA, Lawrence DD, Kemp BL, El-Naggar AK, Cristiano JR, Fang B, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Merritt JA, Mukhopadhyay T, Nesbitt JC, Perez-Soler R, Pisters KMW, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy in oncology: Clinical challenges, needs and prospects, as reflected in p53 gene replacement in NSCLC. Sem Oncol, 1999.
18. Pisters KMW. Diagnosis and prognosis of lung cancer and mesothelioma. Clinical Care Options for Oncology Conference Summaries, 1998.
19. Pisters KMW. NSCLC trials involving thoracic surgery. Clinical Care Options for Oncology Conference Summaries,, 1998.
20. Pisters KMW . BLOT Trial: Phase II trial of induction paclitaxel/carboplatin in clinical stage IB (T2N0), II (T1-2N1, T3N0) and selected IIIA (T3N1) non-small cell lung cancer. Current Clinical Trials in Thoracic Oncology, 1998.
21. Roth, JA, Swisher SG, Merritt JA, Lawrence DD, Kemp BL, Carrasco CH, El-Naggar EK, Fossella FV, Glisson BS, Hong WK, Khuri FR, Kurie JM, Nesbitt JC, Pisters KMW, Putnam JB, Schrump DS, Shin DM, Walsh GL. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 25(8):33-337, 1998.
22. Kris, MG, Pizzo BA, Pisters KMW. Delayed emesis following cisplatin: Progress and prospects. Pharmacy and Therapeutics 22(7S):12S-17S, 1997.
23. Lee, JS, Pisters KMW, Komaki R, Glisson BS, Khuri FR, Schea R, Fossella FV. Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: A preliminary report. Sem Oncol 24(12):S12-52/S12-55, 1997.
24. Pisters, KMW, Kris MG, Bunn PA, Jr, Johnson DH, Ruckdeschel JC, Crowley JJ, Ginsberg RJ,. Induction paclitaxel/carboplatin in early stage non-small cell lung cancer. Sem Oncol 24(12):S12-41/S12-44, 1997.
25. Pisters, KMW, Ginsberg RJ. Induction chemotherapy for early stage lung cancer. Adv Oncol 13:25-29, 1997.
26. Pisters KMW. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology 11:44, 49, 1997.
27. Kris, MG, Pisters KMW, Ginsberg RJ, Rigas JR, Miller VA, Grant SC, Gralla RJ, Heelan RT, Martini N. Effectiveness and toxicity of preoperative therapy in Stage IIIA non-small cell lung cancer including the Memorial Sloan-Kettering experience with induction MVP in patients with bulky mediastinal lymph node metastases (Clinical N2). Lung Cancer 12(1):S47-S57, 1995.
28. Kris, MG, Baltzer L, Hinkley L, Pisters KMW. Strategies to control vomiting caused by anticancer drugs. Adv Biosciences 91:391-397, 1994.
29. Kris, MG, Pisters KMW, Hinkley L . Delayed emesis following anticancer chemotherapy. Support Care Cancer 2:297-300, 1994.
30. Pisters, KMW, Kris MG. Granisetron to prevent vomiting after cancer chemotherapy. Medical Letter , 1994.
31. Kris, MG, Martini N, Gralla RJ, Pisters KMW, Heelan RT. Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases: Focus on five-year survivors. Lung Cancer 9:369-376, 1993.
32. Pisters, KMW, Kris MG. Drugs for nausea caused by cancer chemotherapy. Medical Letter 35(912):124-126, 1993.

Other Articles

1. Pisters KMW Induction chemotherapy in early-stage non-small cell lung cancer. Curr Oncol Rep 5(4):307-308, 2003. PMID: 12781072.

Editorials

1. Pisters KM. Postoperative adjuvant chemotherapy for stage IB NSCLC. Abstracts in Hematology & Oncology 10(2):3-5, 2007.
2. Pisters KMW, Darling G. The IASLC Lung Cancer Staging Project: “The Nodal Zone”. J Thorac Oncol 2(7):583-584, 2007.
3. Pisters KM. Adjuvant chemotherapy for non-small cell lung cancer.The Smoke Clears. . N Engl J Med 352;25(25):2640-2642, 2005. PMID: 15972872.
4. Pisters KM. Adjuvant chemotherapy for resected non-small cell lung cancer. Oncology, 2005.
5. Pisters KM. Editorial on adjuvant chemotherapy. Abstracts in Hematology & Oncology, 2001.
6. Pisters KM. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung. Oncology 11:44,49, 1997.

Abstracts

1. Escalante EP, Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang S, Mendoza T, Liu W, Holmes H, Pisters K, Overman M, Cleeland C. A randomized, double-blind, two period, placebo-controlled crossover trial of a sustained release methylphenidate in the treatment of fatigue in cancer patients. (Poster Session). J Clin Oncol 2012 ASCO Annual Meeting 30, 2012.
2. Luu DC, Mamet R, Zornosa CC, Niland JC, D'Amico TA, Kalemkerian GP, Koczywas M, Pisters K, Rabin MS, Otterson G A. Retrospective analysis of the impact of age on overall survival in patients with non-small cell lung cancer. J Clin Oncol ASCO Proceedings(s), 2012.
3. Lepisto EM, Vandergrift JL, Kalemkerian GP, Pisters KM, Zornosa C, Rabin MS, Reid ME, Zoczywas M, Otterson GA, Ettinger DS. Oncology medication utilization based on Federal Drug Administration (FDA) labeling, NCCN Clinical Practice Guideline (GL) recommendations and evidence for patients with advanced non-small cell lung cancer (NSCLC): An analysis from the National Comprehensive Cancer Network (NCCN) Oncology Outcomes Database. ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Annual Meeting 2011, 2011.
4. Bickel KE, Niland, JC Mamet R, Zornosa CC, Ettinger DS, Pisters K, Otterson GA, Koczywas M, Reid ME, Rabin MS, D'Amico TA, Earle C, Pini TM, Kalemkerian GP. Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (Poster Session). J Clin Oncol ASCO Proceedings 29s, 2011.
5. Zornosa C, Marnet R, Reid ME, Ettinger DS, Otterson GA, Rabin MS, Hayman J, Niland JC, Pisters K. Utilization of adjuvant therapy among completely resected non-small cell lung cancer patients in the National Comprehensive Cancer Network Outcomes Database Project. J Clin Oncol ASCO Annual Meetings Proceedings Part 28(15S), 2010.
6. Vandergrift JL, Marnet R, Zornosa C, Reid ME, Rabin MS, Ettinger DS, Kalemkerian GP, Otterson FA, Niland JC, Pisters K. First-line systemic therapy in metastatic non-small cell lung cancer patients treated at NCCN institutions: An analysis from the NCCN Oncology Outcomes Database Project (Poster Session). J Clin Oncol ASCO Annual Meetings Proceedings Part I 28(15S), 2010.
7. Mehran R, Gil J, Rice D, Swisher S, Lee JJ, Lippman S, Pisters K, Blumenschein G, Hong WK, Tsao AS. Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma (Poster Session). J Clin Oncol ASCO Annual Meetings Proceedings 27(15S), 2009.
8. L. M. Krug, H. Pass, V. W. Rusch, H. L. Kindler, D. Sugarbaker, K. Rosenzweig, J. S. Friedberg, K. Pisters, C. K. Obasaju, N. J. Vogelzang. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I; 25:18S, 2007.
9. J. Uyeki, F. M. Johnson, L. Feng, B. O. Peeples, G. J. Blumenschein, F. V. Fossella, D. D. Karp, K. M. Pisters, D. J. Stewart, B. S. Glisson. Phase II trial of irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) given weekly on alternating weeks with granulocyte colony-stimulating factor support in the treatment of extensive-stage small cell lung cancer. Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I; 25:18S, 2007.
10. K. Pisters, E. Vallieres, P. A. Bunn, J. Crowley, K. Chansky, R. Ginsberg, D. R. Gandara,. Southwest Oncology Group. S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. Journal of Clinical Oncology ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S, 2007.
11. Carmack Taylor CL, Badr H, Basen-Engquist K, Li JH, Gorman A, Pisters K, Fossella F, Schover L. Spousal relationship satisfaction buffers the association between patient and spouse psychological distress when facing lung cancer, 2006.
12. Carmack, Taylor CL, Badr H, Basen-Engquist K, Hall T, Ellickalputhenpura B, Pisters K, Fossella F. Spousal relationships and psychological distress in lung cancer patients and their spouses. Annals of Behavioral Medicine 29:S101, 2005.
13. Pisters K, Vallieres E, Bunn P, Crowley J, Ginsberg R, Ellis P, Meyers B, Marks R, Treat J, Gandara D. S9900: A phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotehrapy in early stage non-small cell lung cancer: Preliminary results. Proc Am Soc Clin Oncol 24, 2005.
14. Vallieres E, Pisters K, Crowley J, Chansky K, Bunn P, Gandara D. S9900: Preliminary surgical results of a phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer. Lung Cancer 49 (suppl 2):s43, 2005.
15. Koshy S, Fossella F, Liu D, Schaerer R, Tsao A, Kies M, Pisters K, Lee J, Herbst R, Zinner R. Asian ethnicity as a predictor of response to gefitinib in non-small cell lung cancer. Lung Cancer 49(suppl 2):S253, 2005.
16. Koshy, S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KMW, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed plus carboplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 23:631a, 2004.
17. Bruera, E, Willey J, Palmer JL, Morice R, Pisters K. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. 8th Congress of the European Association for Palliative Care, 2003.
18. Pisters, K, Ginsberg R, Giroux D, Kris M, Putnam JB, Roberts JR, Johnson D, Crowley J, Bunn PA . Bimodality Lung Oncology Team trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer: Long term followup of a phase II trial. Proc Am Soc Clin Oncol 22:633a, 2003.
19. Zinner, R, Obasaju CK, Fossella FV, Papadimitrakopoulou VA, Pisters KMW, O’Day MR, Peeples BO, Hatfield AK, Hong WK, Herbst RS. Alimta plus carboplatin in patients with advanced non-small cell lung cancer: A phase II trial. Proc Am Soc Clin Oncol 22:642a, 2003.
20. Zinner, RG, Obasaju CK, Fossella FV, Pisters KMW, Papadimitrakopoulou VA, Varghese B, Peeples BO, Haftield AK, Hong WK, Herbst RS. A phase II trial of alimta plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41(suppl 2):223, 2003.
21. Komaki R, Glisson B, Allen P, Fossella F, Liao Z, Stevens C, Blumenschein G, Hong WK, Herbst R, Pisters K.. Hyperfractionated and accelerated thoracic radiation therapy increased survival compared to daily TRT for limited small cell lung cancer patients treated with concurrent chemotherapy. Lung Cancer 41(suppl 2):24, 2003.
22. Blumenschein, GR, Fossella FV, Pisters KMW, Khuri FR, Lu C, Kies MS, Glisson BS, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong WK, Herbst RS. A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Am Soc Clin Oncol 21(314a), 2002.
23. Johnson, FM, Kurie JM, Pisters KM, Fossella FV, Peeples BO, Papadimitrakopoulou VA, Blumenschein GR, Kies MS, Komaki R, Glisson BS . Phase I trial of weekly etoposide, cisplatin, and irinotecan with G-CSF in patients with small-cell lung cancer. Proc Am Soc Clin Oncol 21(312a), 2002.
24. Kim, ES, Mauer AM, Fossella FV, Jamison TA, Kies MS, Pisters KM, Glisson BS, Blumenschein GR, Zinner RG, Tran HT, Windt P, Lie D, Khuri F, Dicke K, Needle M, Vokes EE, Hong WK, Herbst RS. A phase II study of erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002.
25. Tran, HT, Herbst RS, Glisson BS, Pisters KM, Khuri FR, Oh YW, Ordonea NG, Lee P, El-Naggar AK, Hong WK, Zinner RG. Herceptin in combination with cisplatin and gemcitabine in patients with HER2 overexpressing, untreated, advanced, non-small cell lung cancer: final report of a phase II trial. . Proc Am Soc Clin Oncol 21(307a), 2002.
26. Carmack CL, Parker PA, Chavez JL, Baum G, Pisters K, Liao Z, Mehran R, Cohen L. The association between provider characteristics and beliefs about psychosocial care in oncolog. Annals of Behavioral Medicine 43(S1):S93.

Book Chapters

1. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM. Non-small cell lung cancer. In: J Natl Compr Canc Netw. 10. in press, 1236-71, 2012.
2. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members. Non-Small Cell Lung Cancer. In: J Natl Compr Canc Netw. 7. PRR Inc, 740-801, 2010.
3. Pisters, KMW, Mirkovic N, Pass HI, Albain KS. Preoperative Chemotherapy/Radiation Therapy for Early Stage and Locally Advanced Non-Small Cell Lung Carcinoma Disease. In: Lung Cancer: Principles and Practice. Lippincott, 626-649, 2005.
4. Pisters KMW. Multimodality management of early stage lung cancer. . In: Advanced Therapy in Thoracic Surgery. B.C. Decker Inc, 61-67, 2005.
5. Pisters KMW. Combined modality therapy of early stage non-small cell lung cancer. In: Respir Care Clin N Am. 2. Saunders, 191-205, 2003.
6. Vaporciyan, AA, Kelly JF, Pisters KMW . Prevention and management of sequelae of multimodality therapy. In: M. D. Anderson Cancer Series, Lung Cancer. Springer, New York, Inc, 241-255, 2002.
7. Walsh, GL, Pisters KMW, Stevens C. Treatment of stage I lung cancer: The past, present and future. In: Chest Surgery Clinics of North America, 17-38, 2001.
8. Pisters, KMW, Kris MG. Prevention of chemotherapy induced nausea and vomiting. In: Cancer Management: A Multidisciplinary Approach. PRR Inc, 689-700, 2000.
9. Gralla, RJ, Pisters KMW, Kris MG. Chemotherapy-induced nausea and vomiting. In: Cancer Management: A Multidisciplinary Approach. PRR Inc, 735-746, 2000.
10. Pisters KMW . Postoperative adjuvant chemotherapy in non-small cell lung cancer. In: Lung Cancer: Principles and Practice. Lippincott Williams & Wilkins, 769-777, 2000.
11. Pisters, KMW, Kris MG. Treatment-related nausea and vomiting. In: Principles and Practice of Supportive Oncology. Lippincott-Raven, 165-178, 1998.
12. Pisters, KMW, Kris MG. Chemotherapy-induced nausea and vomiting. In: Cancer Management: A Multidisciplinary Approach. PRR Inc, 723-734, 1998.
13. Pisters, KMW, Kris MG. Nausea and vomiting. In: Conn’s Current Therapy. W. B. Saunders Company, 48, 1995.
14. Pisters, KMW, Kris MG, Hilaris B, McCormack PM, Bains MS, Gralla RJ, Martini N. Randomized trial of postoperative vindesine and cisplatin in patients with stage III (T1-3N2M0) non-small cell lung cancer. In: Adjuvant Therapy of Cancer VII. J. B. Lippincott Company, 118-124, 1993.
15. Kris, MG, Tyson LB, Baltzer L, Pisters KMW. Clinical trials in acute cancer chemotherapy-induced vomiting. In: Mechanisms and Control of Emesis. John Libbey Eurotext Limited, 129-139, 1992.
16. Pisters, KMW, Rivera MP, Kris MG. Acute toxicities of cancer therapy. In: Critical Care of the Cancer Patient. Mosby Year-Book, Inc, 1-12, 1991.
17. Pisters, KMW, Kris MG. Management of nausea and vomiting caused by anticancer drugs: State of the art. In: Quality of Life in Current Oncology Practice and Research. Dominus Publishing Co, 107-112, 1991.
18. Pisters, KMW, Kris MG, Gralla RJ, Martini N. Preoperative chemotherapy in stage IIIA non-small cell lung cancer: An analysis of a trial in patients with clinically apparent mediastinal node involvement. In: Adjuvant Therapy of Cancer VI. W. B. Saunders Company, 133-137, 1990.
19. Van Meerbeeck JP, Pisters KM. Preoperative chemotherapy for early-stage non-small cell lung cancer. In: Principles and Practice 4th Edition. 4th, 793-780.

Letters to the Editor

1. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". Chest 134: 1349; author reply 1350, 2008.